$MediciNova (MNOV.US)$Reuters 13 mins ago Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
$MediciNova (MNOV.US)$ MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
2
Report
Quazimofo
:
I appreciate everything you do for this community. You are an all-around great source of information and energy. Thank you, my sweet little human stock scanner.
$MediciNova (MNOV.US)$ MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
Report
No comment yet
Sign in to post a comment
Trending Stocks
Best Growth Stocks Best Growth Stocks
Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.
MediciNova Stock Forum
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
No comment yet